Index

abdominoperineal excision (APE), 105–6. See also extralevator abdominoperineal excision (ELAPE)
for anal cancer, 169
of anorectum, 172
and anterior resection, 107
conventional, 111–2
‘extended’ or ‘cylindrical’, 105–6
gold standard for resection of rectal tumors, 107
intersphincteric, 108–9
‘surgical waist’, 105
‘waisting’ effect, 105–6
abdominoperineal resection, 202
vs. LAR, 210
and short-course radiotherapy, 209–10
ACPGBI, see Association of Coloproctology of Great Britain and Ireland (ACPGBI)
aCR, see apparent complete response (aCR)
acute toxicity of CRT, 206, 208–9
adenocarcinomas, 164, 173–4
adjuvant!, 185
adjuvant chemotherapy, 180
benefits of, 184
bevacuzimab, 183
cetuximab, 183–4
controlled trials of, 181
designing next generation of, 191–2
FLOX, 183
FU, 181
irinotecan, 183
LEU-modulated FU regimens, 182
LV plus FU, 183–2
OX/FU/LEU(FOLFOX), 182–3
in stage II and III patients, 185–6
UFT + fluorouracil + leucovorin as, 98–9
using 5FU/leucovorin + oxaliplatin, 99
adjuvant radiation therapy (RT), 191
advanced adenomas, characteristics and surveillance of, 61
AFAP, see attenuated familial adenomatous polyposis
alcohol consumption, 17
anal canal
definition of, 163–4
and perianal area, 163
anal cancer
adenocarcinoma, 173–4
etiology of, 164
cancer of anal margin, see cancer of anal margin
case study, 174
therapeutic radiotherapy for, 169–71
clinical presentation of, 167–8
clinical staging for, 168–9
deaths from, 170
diagnosis of, 171
histological types of, 166
incidence of, 163
investigation of, 168
malignant melanoma, 174
pathogenesis of, 164–5
patterns of spread, 166–7
premalignant lesions, 165–6
squamous origin, 164
surgical treatment for
abdominoperineal excision, see abdominoperineal excision
anal canal and perianal area, 163–4
complications and disease relapse, 171–2
inguinal metastases, 172–3
lesions at anal margin, 171
results of, 169
anal margin, 164
cancer of
clinical presentation of, 167–8
digital examination of, 168
patterns of spread, 166
treatment by local excision, 169, 171
lesions at, 171
anal melanoma, 164
anal papillomavirus-associated lesions, 165
anal verge, 163–4
anastomosis
in right colon cancer, 96
in sigmoid colon cancer, 94
anogenital intraepithelial neoplasia
grading of, 165–6
natural history of, 173
surgical treatment of, 173
anogenital papillomavirus-associated lesions, 165
anogenital papillomaviruses, 165
anti-EGFR monoclonal antibodies, 250
anti-epidermal growth factor, 183, 184
APE, see abdominoperineal excision (APE)
apparent complete response (aCR), 128–33
assessment tools for, 135–6
clinical follow-up strategy after, 137
efficacy of non-operative treatments, 131
information to patient after, 137
non-operative management, practical issues in, 136–7
vs. pathological complete response, 131–2
pathological examination, thoroughness of, 136
APR, see abdominoperineal resection
Association of Coloproctology of Great Britain and Ireland (ACPGBI), 142
asymptomatic rectal adenocarcinoma, 228
attenuated familial adenomatous polyposis, 280
 Bacillus Calmette Guerin, 181, 190
basaloid tumors, 166
BCG, see Bacillus Calmette Guerin
benzodiazepines, 290, 291
bevacizumab, 184, 250
combination chemotherapy, 246–7, 250
in combination with CRT regimens, 220–1
FOLFOX or FOLFIRI with, 235–6
for stage II and III colon cancer patients, 183
biologic mesh, 118
biologic targeted agents, 220–1, 235–6
for KRAS wild-type patients, 245–7
BRCA mutation, 187
BRCA V600E mutation, 278
breast cancer
commercial tests for, 189
gene profiling for, 189
cachexia syndrome, 295–6
cancer of anal margin
clinical presentation of, 167–8
digital examination of, 168
patterns of spread, 166
treatment by local excision, 169, 171
cancer cachexia, 295–6
cancer-related fatigue
symptoms of, 294, 295
treatment strategies, 294–5
CAP, see capecitabine
capcitabine, 182, 191, 219–20, 252
with irinotecan (CAPEIRI), 220
OX added to, 183
with oxalaplatin (CAPOX), 220
plus oxalaplatin, sequential treatment with, 244–5
sequential treatment with, 244–5
carcinoembryonic antigen, 265
carcinoma in situ, 166
CEA, see carcinoembryonic antigen
central lymph node dissection of right colon cancer, 95
do sigmoid colon cancer, 93, 94
central vascular ligation (CVL), 92
cetuximab, 183–4, 191
combination chemotherapy, 246–7
in combination with CRT regimens, 221
plus either FOLFOX or FOLFIRI, 236
CFL, see chemotherapy-free intervals
chemoradiotherapy (CRT), 219
for anal cancer, 169–71
biologic targeted agents in, 220–1
complications of, 171
cytotoxic drugs integration in, 219–20
postoperative vs. preoperative, 203–5, 219
chemotherapy, intraluminal and systemic, 181
chemotherapy-free intervals
criteria for consideration of, 252
Gercor OPTIMOX trials, 251–2
MRC COIN trials, 252–3
MRC CR06 trial, 251
chemotherapy-induced diarrhea
management of
diphenoxylate atropine, 288
fluoroquinolone, 288
hydration, 288
initiation of opioids, 289
loperamide, 287, 288
octeotide, 289
patient education, 287
NCI criteria for, 287
risk factors for, 286
chemotherapy-induced liver injury, 232–3
chemotherapy-induced nausea and vomiting
anti-emetics for, 290
management of, 290, 291
NCI criteria for, 288
poorly controlled, 291
risk factors for, 289–90
chest-imaging, 265
chromoendoscopy, for colorectal adenomas, 52
circumferential resection margin (CRM), 105
laparoscopic vs. open surgery, 116
Clinical Outcomes of Surgical Therapy (COST) trial, 96, 151
CME, see complete mesocolic excision (CME) coccyx, 113
colon cancer, see colorectal cancer (CRC)
Colon Cancer Laparoscopic or Open Resection (COLOR) trial, 96
colic adenomas, 51–62, see also colorectal cancer (CRC)
characterization of, 52–6
detection of, 52
morphology of, 53–4
granularity, 54
Paris classification, 53–4
overview, 51
surface architecture, 55–6
electronic chromoendoscopy of, 56
Kudo pit pattern, 55–6
colic polyps, see also colorectal cancer (CRC)
characterization of, 52–6
lesion assessment, 53–6
step-by-step approach before polypectomy, 56–7
detection of, 52
granular laterally spreading, 54
large piecemeal resection of, 59
modified Sano’s classification, 56, 57
morphology of, 53–4
smooth laterally spreading, 54
colic resection, 87–100
anatomy for, 87–9
arteries, 87–8
lymphatic vessels, 89
veins, 88–89
bowel resection, 89–91
Kaplan–Meier curves and, 98
lymph node dissection, 89–91
central, 89
Japanese grading of, 91
NTIT, 89
overview, 87
recent studies on, 91–2
colonoscopy, 37–8, 265–6
for colonic polyps, 52
uptake of, 40
colo print assay, 189
colorectal adenocarcinomas, histological subtyping of, 75–8
high grade neuroendocrine carcinomas, 77
intraepithelial lymphocytosis, 75–7
mucinous adenocarcinomas, 77–8
signet ring cell adenocarcinomas, 77
colorectal cancer (CRC)
adjuvant chemotherapy for, see adjuvant chemotherapy for colorectal cancer
criteria of malignancy in, 70
gene expression profiling of, 189
 genetic changes in, 275–6
 BRAF mutation, 187
 DNA methylation patterns, 188
 identification of, 188
 KRAS mutation, 187
 LOH of chromosome 18q, 186–7, 188
 MMR enzyme mutations, 187
 TP53 mutations, 187
 TS expression, 186
 genetic counseling for, see genetic counseling
 histological prognostic factors, 79–80
 perforations at tumor site, 79
 quality of mesorectal excision, 79–80
 venous (large vessel) invasion, 79
 and immune system, balance between, 190
 immunotherapies for, 189–90
 microsatellite instability high, 75–8
 molecular features of, 186
 with no synchronous adenomas, 277–8
 overview, 4
 palliative care, 292–6
 pathogenesis of, 188
 pathology staging of, 70–4
 colorectal resection specimens, 73
 guidelines of AJCC staging system, 71
 oligometastatic colorectal cancer, 74
 postoperative chemotherapy and, 73–4
 serosal cover in colon and rectum, 73
 tumor deposits and, 74
 peri-operative chemotherapy for, 233–4
 positive lymph nodes of, distribution of, 75–8
 sites of recurrence, 263
 sporadic, 277–8
 surgery for, 92–100
 assessment of resectability, 92–3
 exploration of abdominal cavity, 92–3
 laparoscopic, 96–8
 laparoscopic vs. open surgery, 97
 outcome of, 98–100
 right colon cancer, 94–6
 sigmoid colon cancer, 93–4
 surveillance in patients with, 263
 case study of, 268
 follow-up tests and procedures, 264–6
 goals of, 264
 guidelines regarding, 266–7
 meta-analyses, 264
 randomized controlled trials, 264, 266
 treatment selection
 biomarkers for, 186–9
 pathological features, 185–6
 patient age for, 184–5
 personalized therapy, 185–6
 colorectal cancer incidence
 age-standardized rate, 5
 by race-ethnicity and sex, 8
Index

colorectal cancer incidence (Continued)
in selected countries, 4–5
in the United States, 5
worldwide, 4–5

colorectal cancer mortality
by race-ethnicity and sex, 8
in selected countries, 10
in the United States, 6
worldwide, 5–6

colorectal cancer risk factors, 6–18
age, 7
cigarette smoking, 16–17
Crohn’s disease, 12–13
diabetes mellitus, 13–14
diet, 14, 15–18
alcohol consumption, 17
calcium and dairy products, 16
dietary fiber, 15–16
drugs and supplements, 17–18
fish consumption, 16
fruits and vegetables, 15
garlic consumption, 16
red meat consumption, 15
family history, 11–12
folic acid supplementation, 18
genetic predisposition, 9–11
geographic differences, 9
hormone therapy, 18
inflammatory bowel disease, 12
lifestyle, 14
low vitamin D levels, 18
Lynch syndrome, 9–11
obesity, 13
personal medical history, 12–13
Peutz-Jeghers syndrome, 11
physical activity, 14–15
race and ethnicity, 7–9
sex, 7

colorectal liver metastases
epidemiology of, 228–9
imaging and staging work-up, 229
resectability and operability evaluation, 230
response to chemotherapy, 230–1
survival rate, 230
treatment strategies, 231–2
biological agents, 235–6
peri-operative chemotherapy, 233–4
PVE, 234
radiofrequency ablation, 236–7
and repeat hepatectomy, 235
second-line chemotherapy, 235
synchronous metastases, 231–2
colorectal polyps, serrated, 61
COLOR trial, see Colon Cancer Laparoscopic or Open Resection (COLOR) trial
colostomy, for anal cancer, 169
colposcopy of anus, 165
combination chemotherapy
adding cetuximab or panitumumab to, 246
for mCRC treatment, 244–5
combined modality therapy, see chemoradiotherapy
complete mesocolic excision (CME), 92
condylomas, surgical excision of, 173
Contact and Transanal Endoscope Microsurgery (CONTEM) trials, 143
contact radiotherapy
combining with EBRT, 142–3
in early rectal cancer, 141–2
future trials in, 143
CONTEM trials, see Contact and Transanal Endoscope Microsurgery (CONTEM) trials
conventional neoadjuvant chemoradiotherapy (CRT)
and apparent complete response, 128–33
assessment tools for, 135–6
efficacy of non-operative treatments, 131
vs. pathological complete response, 131–2
pathological examination, thoroughness of, 136
Brazilian experience, 129–31
meta-analysis of, 140
Conventional vs. Laparoscopic-Assisted Surgery in Colorectal Cancer (CLASICC) trial, 105
conversion chemotherapy for liver metastases, 247
chemotherapy plus biologics, 249
anti-EGFR monoclonal antibodies, 250
bevacizumab, 250
combination chemotherapy, 247–9
corticosteroids, 294
COST trial, see Clinical Outcomes of Surgical Therapy (COST) trial
CRM, see circumferential resection margin (CRM)
Crohn’s disease, 12–13
CRT, see chemoradiotherapy
CVL, see central vascular ligation (CVL)
cytotoxic and immune therapy, combination of, 181
cytotoxic drugs
capcitabine, see capcitabine
tirinotecan, 220
D3 dissection, see central lymph node dissection
diabetes mellitus, 13–14
diarrhea, chemotherapy-induced, see chemotherapy-induced diarrhea
diminutive and small polyps, resection of, 57–8
disappearing liver metastases, 233
DNA binding (ZB) regions, mutations in, 187
DNA methylation studies, 188
DNA mismatch repair (MMR) enzyme mutations, 187
EBRT, see external beam radiotherapy (EBRT)

EGFR-targeted agents, 246

ELAPE, see extralevator abdominoperineal excision (ELAPE)

electronic chromoendoscopy, for colonic polyps, 56

EMR, see endoscopic mucosal resection (EMR)

detection technique

of early (T1) adenocarcinoma, 70

of larger sessile and flat lesions, 58–9

endoscopic submucosal dissection (ESD)

for colorectal lesions, 59–60

of flat polyp, 60

English Bowel Cancer Screening Programme, 43

EPCAM mutations, 276–7

epidermal growth factor receptor (EGFR), 236

erlotinib, 221

ESSO conference, see European Society of Surgical Oncology (ESSO) conference

European Society of Surgical Oncology (ESSO) conference, 155

excavated lesions, 53–4

excision biopsy, with TEMS for early rectal cancer, 139–40

external beam radiotherapy (EBRT), 142–3

extralevator abdominoperineal excision (ELAPE), 104–20. See also abdominoperineal excision (APE)

assessment and staging, 109–11

coccyx and, 113

definition of, 111–3

historical aspects of, 106–7

indications for, 108–9

in low rectal cancer, 108

neoadjuvant and adjuvant therapies, 119–20

overview, 104–6

patients’ morbidity and quality of life, 118–9

preoperative preparation for, 109–11

radiological staging and, 110–1

surgical technique, 113–8

biological mesh, 118

laparoscopic vs. open surgery, 116–7

myocutaneous flap, 117–8

omentoplasty, 118

outcome related to position, 114–5

patient positioning, 113–4

perineal wound complications of, 117

position and sequence for perineal dissection, choice of, 115–6

faecal immunochemical testing (FIT), 32–5

advantage of, 34–5

vs. gFOBT, 33–4

qualitative, 33

quantitative, 33, 34

sensitivity, 33–5

familial adenomatous polyposis (FAP), 11, 62, 280–1

familial CRC, 11–12

FAP, see familial adenomatous polyposis (FAP)
fentanyl, 293

18F-fluorodeoxyglucose-positron emission tomography (FDG-PET), 265

FIT, see faecal immunochemical testing (FIT)

flat lesions, 53

EMR of, 58–9

ESD of, 60

granularity of, 54

flexible sigmoidoscopy (FS), 35–7

colorectal cancer incidence, reduction in, 35–6

SCORE trial, 36

UK Flexiscope trial, 36–7

FLOX, 182–3, 246

5-fluouracil, 184, 188, 191

in combination with LV, 181–2, 185

cytotoxicity efficacy, 182

LEU-modulated, 182

and OX/FU/LEU, comparison of, 182–3

and Me-ccnu, 181

FOLFIRI

and bevacizumab combination, 250

FOLFIRI plus cetuximab, 250

FOLFOX, 250

FU, see 5-fluorouracil

5-FU

and CFI, 251

oral pro-drug of, 219–20

oxaliplatin and irinotecan, sequencing of, 244

pCR rate of, 219

FU-based chemotherapy, 233

5-FU-based chemotherapy, 207, 208

FU-based trials, 185

functional liver remnant, 234

and portal vein embolization, 234

gelitinib, 221

gene expression profiling of tumors, 189

genetic counseling

familial adenomatous polyposis, 280–1

hepatic flexure adenocarcinoma, 275–6

Lynch syndrome, 276–9

multiple polyps, 280

MUTYH-associated polyposis, 281–2

and psychosocial implications, 283

and testing, criteria for, 282–3

genetic predisposition, 9–11

universal screening, 9–11

genetic testing, 278, 282–3

genital papillomavirus infection, 165

Genomic Health, 189
Gercor OPTIMOX trials, 251–2
German Colonoscopy Screening Programme, 34
gFOBT, see guaiac based faecal occult blood testing (gFOBT)
groin nodes, enlargement of, 172

guaiac based faecal occult blood testing (gFOBT), 29–32
  Danish study, 31
  Dukes Stage A, 30, 31
  French study, 31
  Haemoccult II test, 29–32
    ‘halo’ effect in, 31
  Nottingham study, 31
  sensitivity of, 29–30
GWAS, see genome-wide association studies (GWAS)

haemoccult II gFOBT, 29–32
vs. quantitative FIT, 33
haloperidol, 293
health organizations, guidelines regarding surveillance produced by, 266
hepatectomy, for colorectal metastases, 235
hepatic flexure adenocarcinoma, 275
hereditary non-polyposis colorectal cancer (HNPCC), see Lynch syndrome (LS)
high-grade anal intraepithelial lesions, 166
high grade dysplasia, 70
high grade neuroendocrine carcinomas, 77
high throughput genomic scanning technology, 188
HIV infection, see human immunodeficiency virus infection
HPVs, see human papillomaviruses
human immunodeficiency virus infection and anal cancer, 164
of anogenital area, 173
human papillomaviruses, 164–5
hypertrophy, 234
hypogonadism, 295

immune stimulants, 181
immunohistochemistry, 80–1
  loss of MLH-1 nuclear expression, 80
  and pCR-based microsatellites, 80–1
  and sub-typing of MSI-H colorectal cancer, 80
immunomodulators, for AIN, 173
immunotherapies for colon cancer, 189–90
inferior mesenteric artery, 88
inflammatory bowel disease, 12
inguinal metastases, 172–3
intraepithelial lymphocytosis, 75–7
  marked, 76
intraepithelial neoplasia, 173
IR, see irinotecan

irinotecan, 183, 220, 235
  5-FU and oxaliplatin, sequencing of, 244
  sequential treatment with, 244–5
  irinotecan-containing chemotherapy, complications of, 232

Japanese Society for Cancer of the Colon and Rectum (JSCCR), 91
JCOG0205 trial, 99–100
JCOG0404 trial, 98
JSCCR, see Japanese Society for Cancer of the Colon and Rectum (JSCCR)

Kaplan–Meier curves, 98
KPP, see Kudo pit pattern (KPP)
KRAS mutation, 187, 236
Kudo pit pattern (KPP), 55–6
classification of colonic polyps, 55

laparoscopic surgery, 96–8
COLOR II study, 155
current status of, 153–5
evidence base for, 153
meta-analysis of, 153–5
NICE guidance for, 152
oncological aspects of, 152
vs. open surgery, 97, 116–7, 154
overview, 150–2
pre-determined sequence, 156
randomized controlled trials, 151
rectal dissection in tight pelvis, 156
of rectum, 117
splenic flexure mobilization, 156
LARC, see locally advanced rectal cancer (LARC)
lesion assessment
  morphology, 53–4
  granularity, 54
  Paris classification, 53–4
  surface architecture, 55–6
electronic chromoendoscopy for, 56
Kudo pit pattern, 55–6
LEU, see leucovorin
leucovorin
  in combination with OX and FU, 182–3
  modulated FU, 182, 183
LEV, 190
levamisole, in combination with FU, 181–2, 185
liver injury, chemotherapy-induced, 232–3
liver metastases, 228
disappearing, see radiographic complete responses
synchronous, management of, 231–2
local recurrence (LR)
causes of, 202, 210
in Polish trial, 207
and preoperative long-course RT, 210–1
and preoperative RT with TME, 202–3
and preoperative short-course RT, 201–2, 205
Index

local resection
of early rectal cancer, 137–9
meta-analysis of, 140
role in complete response, 140–1
locally advanced rectal cancer (LARC), 219
long-course radiotherapy (RT), 201
advantages of
addition of chemotherapy, 212
low postoperative complications, 211
lower late toxicity, 211–2
resectability, 210–1
sphincter preservation, 209–10
tumor downstaging, 210–1
postoperative vs. preoperative CRT, 203–5
randomized control trials of, 205–8
short- and, difference between, 205–8
loss of heterozygosity (LOH) of chromosome 18q, 186–7
low rectal cancer, 108
LV, see levamisole
lymph node metastases, 75–8, 166, 171
lymphatic vessels, 89
Lynch syndrome (LS), 9–11
clinical presentation of, 276
mismatch repair gene mutations, 278
MSI and IHC analysis, 277–8
patient evaluation, 277
malignant melanoma, 174
MAP, see MutYH associated polyposis (MAP)
mesenteric margin, 74–5
mesorectal margin, 74
meta-analyses, 264–5
metachronous metastases, 235
metastatic colorectal cancer (mCRC)
chemotherapy-free intervals, see chemotherapy-free intervals
conversion chemotherapy for, 247
chemotherapy plus biologics, 249–50
combination chemotherapy, 247–9
development of, 243
metastatic colorectal cancer, treatment of
KRAS wild-type patient management, 245
EGFR-targeted agents, 246
VEGF-targeted agents, 246
sequential vs. combination chemotherapy
DCG CAIRO trial, 244–5
MRC FOCUS trial, 244
methadone, 293
methylphenidate, 294
microsatellite instability (MSI) analysis, 275
for LS, 277–8
microsatellite instability high (MSI-H) colorectal cancer, 75–8
histological features of, 76
marked intraepithelial lymphocytosis in, 76
mismatch repair enzymes, MSI and IHC for,
278–9
mismatch repair gene mutations
genetic testing of, 278
LS associated with, 276–7
mitomycin, 171
MLH1 mutation, 276, 278
MLH2 mutation, 276
modified (m) FOLFOX7, 251–2
morphine, 292–3
MOSAIC trial, 99–100, 182, 185
MRC COIN trials, 252–3
MRC CR06 trial, 251
MSI-H6 mutations, 276
MSI colon cancers
causes of, 187
immunotherapies for, 190
testing for, 187–8
mucinous adenocarcinomas, 77–8
differentiated, 76
multifocal genital intraepithelial neoplasia, 166
multiple polyps, 62
MutYH associated polyposis (MAP), 11, 62
MUTYH-associated polyposis (MAP), 281–2
myocutaneous flap, 117–8
National Cancer Research Institute (NCRN), 135
National Comprehensive Cancer Network, guidelines on clinical trial, 185–6
National Institute for Clinical Excellence (NICE), 151
National Surgical Adjuvant Breast and Bowel Project (NSABP), 203
nausea and vomiting, chemotherapy-induced, see chemotherapy-induced nausea and vomiting
NCRN, see National Cancer Research Institute (NCRN)
nCRT, see neoadjuvant chemoradiotherapy
neoadjuvant chemoradiotherapy, 191
conventional, see conventional neoadjuvant chemoradiotherapy (CRT)
factors affecting response to, 133–6
initial tumor stage, 133
type of therapy given, 133–4
future of non-operative treatment after, 143–4
histopathological response to, 78–9
radiosensitizing systemic agents in, 144
with TEMS, 139–40
tumor assessment after, timing of, 134–5
tumor regression system of response to, 78
neoadjuvant chemotherapy
biological agents, 235–6
chemotherapy-induced liver injury, 232–3
and disappearing liver metastases, 233
peri-operative chemotherapy, 233–4
PVE, 234
and repeat hepatectomy, 235
second-line chemotherapy, 235
for synchronous liver metastases, 231–2
Index

NICE, see National Institute for Clinical Excellence (NICE)
non-binding (NZB) regions, mutations in, 187
non-surgical therapy for anal cancer
chemoradiation therapy, 169–71
complications of, 171–2
non-touch isolation technique (NTIT), 89
NTIT, see non-touch isolation technique (NTIT)
obesity, 13
octeotide, 289
octreotide, 293
OIN, see opioid-induced neurotoxicity
oligometastatic colorectal cancer, 74
omentoplasty, 118
opioid-induced neurotoxicity, 293
opioid induced sedation, treatment of, 296
opioid rotation, 293
OS, see overall survival
overall survival
and preoperative RT with TME, 202–3
with preoperative short-course RT, 201–2
OX, see oxaliplatin
oxaliplatin, 184, 191, 220, 235, 251-2
added to CAP(XELOX), 183
added to FU/LEU schedule, 182-3
5-FU and irinotecan, sequencing of, 244
in MOSAIC and NSABP C-07 trials, 185
panitumumab, 246
combination chemotherapy, 246–7
paragoic, 289
Paris classification, of polyp morphology, 53–4
pathological complete response, 126, 219
postoperative vs. preoperative CRT, 204–5
short vs. long-course radiotherapy, 206, 210
patient controlled analgesia, 292–3
PCA, see patient controlled analgesia
pCR, see pathological complete response
pCR rate
of CRT with CAPOX plus bevacizumab,
220–1
of 5-FU, 219–20
pedunculated polyps, resection technique for,
58
perineal area, reconstruction of, 172
perineal dissection
on caudal surface of levators, 111
excision of anal canal in, 111
position and sequence for, choice of, 115–6
peri-operative chemotherapy, 233–4
Peutz-Jeghers syndrome, 11
photodynamic therapy, for AIN, 173
PIK3CA mutation, 18
PMS2 mutations, 276
polyposis syndrome, 62
portal vein embolization (PVE), 234
postoperative complications, 211
protruding lesions, 53
psychosocial implications, 283
pT1 tumors, 138
race and ethnicity, 7–9
and colorectal cancer mortality, 8
radical surgery, 170
radiofrequency ablation, of colorectal liver metastases, 236–7
radiographic complete responses, 233
radiosensitizers, 221
radiosensitizing systemic agents, 144
radiotherapy
appearance of primary site after, 171–2
and chemoradiation, comparison of, 170–1
for inguinal metastases, 172
randomized controlled trials, 201–2, 264, 266
Australian Intergroup Trial, 207
Berlin Rectal Cancer Trial, 208
Polish rectal trial, 205, 207
Stockholm III study, 207–8
rectal cancer
molecular characteristics of, 190–1
spread of, 202
treatment approaches, 191
treatment approaches
long-course radiotherapy, see long-course radiotherapy
preoperative RT with TME, 202–3
preoperative vs. postoperative CRT, 219
short-course radiotherapy, see short-course radiotherapy
rectal cancer surgery, see extralevator abdominoperineal excision (ELAPE)
rectovaginal fistula, 172
resectability and CRT, 210–1
resectable metastatic disease, 230
resection margins, 74–5
4b colorectal cancers and, 75
distal margin, 75
mesenteric margin, 74–5
mesorectal margin, 74
resection technique
complications and follow-up, 60–1
for diminutive and small polyps, 57–8
for pedunculated polyps, 58
residual tumor, treatment of, 171–2
RFA, see radiofrequency ablation
right colon cancer, surgery for, 94–6
anastomosis, 96
central lymph node dissection, 95
mobilization of right colon, 94–5
right portal vein ligation with in situ splitting, 234
robotic rectal cancer surgery, 157–60
  feasibility of, 157–8
  hybrid operation, 159
  lack of good evidence to support, 158
  left colonic mobilization, 160
  patient selection for, 158
  published series of, 158
  technological advances of robotic system and, 159
Scottish Bowel Screening Programme, 33
Scottish gFOBT Programme, 41
SCPRT, see short-course preoperative radiotherapy (SCPRT)
screening, for colorectal cancer, 27–50
  adverse effects of, 40–2
  ‘all cause’ mortality and, 41–2
  colonoscopy, 37–8
  economics of, 42–3
  faecal immunochemical testing, 32–5
  advantage of, 34–5
  and colonoscopy, 34–5
  vs. gFOBT, 33–4
  qualitative, 33
  quantitative, 33, 34
  sensitivity, 33–5
flexible sigmoidoscopy, 35–7
  colorectal cancer incidence, reduction in, 35–6
SCORE trial, 36
UK Flexiscope trial, 36–7
guaiac based faecal occult blood testing, 29–32
  Danish study, 31
  Dukes Stage A, 30, 31
  French study, 31
  Haemoccult II test, 29–32
  ‘halo’ effect in, 31
  Nottingham study, 31
  sensitivity of, 29–30
  novel approaches to, 43
overview, 28–9
radiology, 38–9
uptake in population, 39–40
sequential vs. combination chemotherapy, 244–5
  serosal cover, in colon and rectum, 73
serrated colorectal polyps, 61
sexually transmissible agent and female genital cancer, association between, 164
short-course preoperative radiotherapy (SCPRT), 128
  acute toxicity of, 140
  for T1 and T2 tumors, 139–40
short-course radiotherapy (RT), 128
  advantages of
    compliance, 209
    costs/convenience, 209
    lower rates of acute toxicity, 208–9
long- and, difference between, 205–8
preoperative
  continuous infusion 5-FU concomitant to, 219
  randomized control trials of, 201–2, 205–8
  with TME, 202–3
sigmoid colon adenocarcinoma
  case study, 180
sigmoid colon cancer, surgery for, 93–4
  anastomosis, 94
  central lymph node dissection, 93, 94
  mobilization of left colon, 93
  signet ring cell adenocarcinomas, 77
sinusoidal obstruction syndrome, 232, 236
SMI, see submucosal invasion (SMI)
sphineter preservation rate, 203, 205, 209–10
steatohepatitis, 232–3
STK11 gene, 11
submucosal invasion (SMI), 54
superior mesenteric arteries, 88
synchronous liver metastases, management of, 231–2
T4b colorectal cancers, 75
TEMS, see transanal endoscopic microsurgery (TEMS)
testosterone replacement therapy, 295–6
thymidylate synthase, 186
tincture of opium, 289
TME, see total mesorectal excision; total mesorectal excision (TME)
TNM staging
  in colorectal cancer, 70–4
  layers of colorectal wall and pericolonic tissue with, 72
  total mesorectal excision, 201
  with short-course preoperative RT, 202, 207
  total mesorectal excision (TME), 92
  for early-stage rectal cancer, 127–8
  overview, 104–5
TP53 mutations, 187
transanal endoscopic microsurgery (TEMS), 128
  for early rectal cancer, 139–40
  efficacy of, 138
  neoadjuvant radiotherapy and excision biopsy with, 139–40
TRT, see testosterone replacement therapy
TS, see thymidylate synthase
tumor deposits, in pericolonic/perirectal soft tissue, 74
  tumor downstaging, 209, 210
UICC, see Union for International Cancer Control
ulcerative colitis, 179–80
Index

ultrasonography, 265
Union for International Cancer Control, 168–9
vascular endothelial growth factor (VEGF) inhibitors, 235
VEGF-targeted agents, 246
vertical rectus abdominus muscle (VRAM) flap, 117–8
visceral peritoneal, 73
vomiting, chemotherapy-induced, see chemotherapy-induced nausea and vomiting
VRAM flap, see vertical rectus abdominus muscle (VRAM) flap
warts, 165
XELOX, 246
XEROXA trial, 99–100